- Condition
- Rheumatoid Arthritis
- Patient profile
- F, age band 45–54, Germany
- Outcome scale
- DAS28 (lower is better)
DAS28 follow-up over 12 months for a German patient with seropositive rheumatoid arthritis treated with an intravenous Wharton's Jelly MSC autoimmune program in Istanbul.
DAS28 improvement in this case occurred against a background of optimized DMARD therapy. The case does not isolate the contribution of MSCs and is not a predictor of any other patient's outcome.
DAS28 timeline
DAS28 combines tender joint count, swollen joint count, ESR or CRP, and patient global assessment. <2.6 = remission; 2.6–3.2 = low; 3.2–5.1 = moderate; >5.1 = high disease activity.
| Timepoint | DAS28 | Δ vs baseline |
|---|---|---|
| Baseline | 5.4 | — |
| Day 90 | 4.6 | -0.8 |
| Day 180 | 3.9 | -1.5 |
| Day 365 | 3.7 | -1.7 |
Seropositive rheumatoid arthritis (RF+, anti-CCP+), 11 years since diagnosis. On combination DMARD therapy with methotrexate plus a biologic. Persistent moderate disease activity (DAS28 5.4) at baseline despite optimized DMARD regimen.
Intravenous Wharton's Jelly MSCs across two infusions with structured autoimmune workup (CBC, CMP, hsCRP, ESR, anti-CCP, RF, lipid and metabolic panel). All baseline DMARD therapy continued in coordination with the patient's home rheumatologist.
DAS28 captured at Days 90, 180 and 365 by the home rheumatologist. Patient reported reduced morning stiffness from ~90 minutes to ~25 minutes by Day 180 and maintained at Day 365. No DMARD escalation required in the 12-month window.
Mild fatigue for 48 hours post infusion. No infusion reaction. No new infections.
